Yan Leyfman, MD
@yleyfman.bsky.social
Physician | Executive Director & Host MedNews Week | Medical Correspondent | Conference Director | Journal Editor | Educator | Research #Oncology #COVID19 #Immunotherapy #celltherapy #tcellrx #CART #bmtsm #MedSKY #ONCSKY | About Me: http://nyti.ms/2VG3gUK
Our memento that will live on forever (your presentation on MedNews Week Keynote Conference): www.onclive.com/view/transla...
#sarcoma #leader #pioneer #cancer #medicine #oncology @sitemancenter.bsky.social
#sarcoma #leader #pioneer #cancer #medicine #oncology @sitemancenter.bsky.social
Translating Metabolic Therapies Into Sarcoma | OncLive
Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.
www.onclive.com
November 10, 2025 at 3:23 AM
Our memento that will live on forever (your presentation on MedNews Week Keynote Conference): www.onclive.com/view/transla...
#sarcoma #leader #pioneer #cancer #medicine #oncology @sitemancenter.bsky.social
#sarcoma #leader #pioneer #cancer #medicine #oncology @sitemancenter.bsky.social
You are now watching over all of us, Dr. Van Tine, as the field of sarcoma and oncology continues to grow from the profound impact you made.
Thank you for being you. It was our privilege to know you. ❤️
Thank you for being you. It was our privilege to know you. ❤️
November 10, 2025 at 3:23 AM
You are now watching over all of us, Dr. Van Tine, as the field of sarcoma and oncology continues to grow from the profound impact you made.
Thank you for being you. It was our privilege to know you. ❤️
Thank you for being you. It was our privilege to know you. ❤️
The great ones leave us early, but they teach us the most important lessons: about passion, perseverance, humility, and purpose. I can only aspire to be half the innovator and impact-maker that Dr. Brian Van Tine was.
November 10, 2025 at 3:23 AM
The great ones leave us early, but they teach us the most important lessons: about passion, perseverance, humility, and purpose. I can only aspire to be half the innovator and impact-maker that Dr. Brian Van Tine was.
I recently purchased his oncology textbook, hoping to have it autographed when our paths crossed again at ASCO. Sadly, that chance will never come. But his legacy—both scientific and human—will continue to inspire countless others.
November 10, 2025 at 3:23 AM
I recently purchased his oncology textbook, hoping to have it autographed when our paths crossed again at ASCO. Sadly, that chance will never come. But his legacy—both scientific and human—will continue to inspire countless others.
Dr. Van Tine was the kind of person who made himself available to everyone—trainees, junior faculty, and colleagues alike. He treated each person with deep respect and genuine kindness.
November 10, 2025 at 3:23 AM
Dr. Van Tine was the kind of person who made himself available to everyone—trainees, junior faculty, and colleagues alike. He treated each person with deep respect and genuine kindness.
His energy radiated across every room, as did his brilliant insights and infectious enthusiasm for oncology.
I was fortunate to host him as a Keynote Speaker on MedNews Week, where he generously shared his wisdom, humor, and vision for the future of sarcoma research.
I was fortunate to host him as a Keynote Speaker on MedNews Week, where he generously shared his wisdom, humor, and vision for the future of sarcoma research.
November 10, 2025 at 3:23 AM
His energy radiated across every room, as did his brilliant insights and infectious enthusiasm for oncology.
I was fortunate to host him as a Keynote Speaker on MedNews Week, where he generously shared his wisdom, humor, and vision for the future of sarcoma research.
I was fortunate to host him as a Keynote Speaker on MedNews Week, where he generously shared his wisdom, humor, and vision for the future of sarcoma research.
Grateful to contribute to this timely discussion with Ariana Pelosci & Cancer Network on the evolving landscape of leukemia treatment and what this means moving forward.
www.cancernetwork.com/view/clinica...
@onclive.bsky.social
www.cancernetwork.com/view/clinica...
@onclive.bsky.social
Clinical Implications Remain After Dasatinib CRL in CML/ALL | CancerNetwork
The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.
www.cancernetwork.com
October 30, 2025 at 5:33 AM
Grateful to contribute to this timely discussion with Ariana Pelosci & Cancer Network on the evolving landscape of leukemia treatment and what this means moving forward.
www.cancernetwork.com/view/clinica...
@onclive.bsky.social
www.cancernetwork.com/view/clinica...
@onclive.bsky.social
Standard dasatinib (Sprycel) remains accessible, effective, and unchanged for patients. The delay only affects the availability of the HyNap formulation, which may ultimately offer improved patient convenience and tolerability.
October 30, 2025 at 5:33 AM
Standard dasatinib (Sprycel) remains accessible, effective, and unchanged for patients. The delay only affects the availability of the HyNap formulation, which may ultimately offer improved patient convenience and tolerability.
While the FDA’s third Complete Response Letter introduces a temporary delay, it’s important to note that this was due to manufacturing-related issues, not the drug’s well-established clinical profile.
October 30, 2025 at 5:33 AM
While the FDA’s third Complete Response Letter introduces a temporary delay, it’s important to note that this was due to manufacturing-related issues, not the drug’s well-established clinical profile.
The oncology community has been closely following the development of the amorphous, lower-dose formulation of dasatinib (Dasynoc) under HyNap technology—an approach designed to optimize adherence and long-term tolerability in CML and ALL.
October 30, 2025 at 5:33 AM
The oncology community has been closely following the development of the amorphous, lower-dose formulation of dasatinib (Dasynoc) under HyNap technology—an approach designed to optimize adherence and long-term tolerability in CML and ALL.
Thank you for your support
September 25, 2025 at 12:01 AM
Thank you for your support
I’m energized to help grow this rising research journal, drive forward novel science, and translate the latest breakthroughs into better care for clinicians and patients around the world. 🔬🩺
Excited to contribute, learn, and collaborate. 🌍
Excited to contribute, learn, and collaborate. 🌍
September 23, 2025 at 10:53 PM
I’m energized to help grow this rising research journal, drive forward novel science, and translate the latest breakthroughs into better care for clinicians and patients around the world. 🔬🩺
Excited to contribute, learn, and collaborate. 🌍
Excited to contribute, learn, and collaborate. 🌍
Thank you for your support
September 23, 2025 at 9:41 PM
Thank you for your support
Thank you for your support.
September 20, 2025 at 8:23 PM
Thank you for your support.
Thank you for your support.
September 19, 2025 at 4:18 AM
Thank you for your support.
Stories like these remind us that behind every healthcare career lies a deeply personal “why.”
💭 What’s yours?
🎧 Listen to the full interview here: pod.link/1823798473/e...
#chernobyl #physician #medicine #healthcare #humanity
💭 What’s yours?
🎧 Listen to the full interview here: pod.link/1823798473/e...
#chernobyl #physician #medicine #healthcare #humanity
pod.link
September 3, 2025 at 4:25 AM
Stories like these remind us that behind every healthcare career lies a deeply personal “why.”
💭 What’s yours?
🎧 Listen to the full interview here: pod.link/1823798473/e...
#chernobyl #physician #medicine #healthcare #humanity
💭 What’s yours?
🎧 Listen to the full interview here: pod.link/1823798473/e...
#chernobyl #physician #medicine #healthcare #humanity